جستجوی استاد راهنمای دانشگاهی

• Neurosurgery
• Functional Neurosurgery
• Neuromodulation
• +۳ مورد دیگر

Zion Zibly, MD, MBA is an Associate Professor in the Department of Neurosurgery at Yale School of Medicine . He holds multiple leadership roles including Director of the Center of Neuromodulation , Director of the Center of Neurosurgical Cancer Pain , and Head of Stereotactic & Functional Neurosurgery and the Focused Ultrasound Institute . Previously served as Chair of Neurosurgery at Sheba Medical Center after graduating from Technion’s Faculty of Medicine (MD) and Coller School of Management (MBA). Research Interests: Specializes in Neuromodulation for movement disorders (Parkinson’s, tremors, dystonia), Deep Brain Stimulation , Gene Therapy for pediatric neurodegenerative conditions, Oncological Neurosurgery , and Neurological Pain Management . Combines Functional Neurosurgery with Focused Ultrasound technology. Scientific Contributions: Participated in pioneering Alzheimer’s brain stimulator procedures and Gene Therapy applications. Active member of the North American Association of Functional Neurosurgery and Israeli Neurosurgical Society . Clinical Expertise: Implantation of electrostimulators for Parkinson’s and essential tremor, treatment of Benign/Malignant CNS Tumors , and management of Neurological Pain Conditions . Affiliated with Yale Cancer Center and Center for Brain & Mind Health .

Fuchsia Howardمشاهده پروفایل

دانشیار

• Oncology Nursing
• Reproductive Health
• Critical Care Survivorship
• +۵ مورد دیگر

Fuchsia Howard, PhD, RN serves as an Associate Professor and PhD Coordinator at the University of British Columbia School of Nursing. Her office is located at T201 2211 Wesbrook Mall, Vancouver, BC V6T2B5, with contact via phone (1-604-822-4372) and email (fuchsia.howard@ubc.ca). Her research spans oncology nursing, reproductive health, critical care survivorship, and health equity . She investigates fertility preservation for cancer patients, endometriosis-associated dyspareunia management, and digital health interventions for sexual health. Her work emphasizes patient-reported and family-reported outcomes , particularly in chronic disease management and post-ICU recovery. Current projects address social determinants of health in critical illness survivorship and destigmatizing design for sexual health technologies. Her recent publications (2023-2025) demonstrate strong focus on Patient-centered outcome measures in oncology and gynecology Digital resource development for endometriosis and fertility challenges Family caregiver roles in critical illness recovery Health equity in Canadian cancer care systems Key methodologies include qualitative studies, scoping reviews, and mixed-methods approaches. As PhD Coordinator, she guides nursing doctoral candidates though specific students aren't listed in available materials. Her work connects with clinical practice through collaborations with BC Cancer and UBC-affiliated hospitals.

Christopher D. Abrahamمشاهده پروفایل

دانشیار

• Radiation Oncology
• Neuro-Oncology
• Brain Tumor Treatment
• +۴ مورد دیگر

Christopher D. Abraham, MD is an Associate Professor of Radiation Oncology and Associate Professor of Medicine at Washington University School of Medicine in St. Louis. He is affiliated with the Siteman Cancer Center, Brain Tumor Center, and Institute of Clinical and Translational Sciences (ICTS). Dr. Abraham practices at multiple locations including the Center for Advanced Medicine Radiation Oncology Center, Barnes-Jewish West County Hospital, and Siteman Cancer Center – North County. His clinical work focuses on radiation oncology with expertise in treating brain tumors and other cancers. Dr. Abraham completed his Medical Degree at Saint Louis University School of Medicine in 2011 and his Residency in Radiation Oncology at Barnes-Jewish Hospital and Washington University School of Medicine in 2016. He earned his BS in Radiologic Science from the Medical College of Georgia in 2004. Dr. Abraham's research focuses on advancing radiation therapy techniques, particularly in stereotactic radiosurgery for brain metastases, hippocampal-avoidance whole brain radiation therapy, and innovative approaches for glioblastoma treatment. His work demonstrates a strong emphasis on optimizing radiation delivery while minimizing neurocognitive side effects. He has pioneered simulation-free radiation therapy techniques that expedite treatment planning, particularly for palliative care patients. His research also explores the integration of AI and large language models in radiation oncology workflows and insurance appeals processes. Analysis of Dr. Abraham's recent publications reveals a clear research trajectory focused on improving precision in radiation therapy for brain tumors, with particular attention to hippocampal protection, adaptive planning techniques, and combined modality approaches. His work spans clinical trials, technical innovations in treatment planning, and translational research connecting imaging with treatment outcomes. The increasing citation counts of his work, particularly his 2023 paper on simulation-free radiation therapy which has 34 citations, demonstrates growing impact in the field. While specific awards are not listed in the provided information, Dr. Abraham's work has accumulated 536 citations according to Scopus metrics, indicating significant scholarly impact. His research has been referenced in clinical guidelines and policy sources, demonstrating translational relevance to clinical practice. Dr. Abraham actively collaborates with multidisciplinary teams including neurosurgeons, medical oncologists, and physicists. His work on the NRG Oncology/RTOG 0631 trial demonstrates involvement in large cooperative group studies. He has contributed to efforts examining insurance policy adherence to radiation oncology guidelines, showing engagement with healthcare systems issues. As a key member of the Brain Tumor Center at Siteman Cancer Center, Dr. Abraham participates in comprehensive brain tumor care teams that integrate surgical, medical, and radiation oncology approaches. His work with the Institute of Clinical and Translational Sciences highlights his commitment to translating research findings into clinical practice. Current research directions include exploring simulation-free radiation therapy techniques, optimizing hippocampal-sparing approaches, and investigating novel combinations of radiation with immunotherapies.

• Gastrointestinal Oncology
• Radiation Oncology
• Stereotactic Body Radiotherapy (SBRT)
• +۹ مورد دیگر

Kimberly L. Johung, MD, PhD is an Associate Professor of Therapeutic Radiology at Yale School of Medicine, holding multiple leadership positions including Vice Chair for Education, Director of the Residency Training Program, Chief of the Gastrointestinal Radiotherapy Program, and Chief of the VA Radiotherapy Program. She practices at Smilow Cancer Hospital and provides radiation oncology services at the Veteran Affairs Connecticut Healthcare System in West Haven. Dr. Johung completed her medical education at Yale University School of Medicine (MD, 2008) and earned her PhD from Yale University (2007). Her residency training was at Yale-New Haven Hospital (2013) following an internship there in 2009. Her undergraduate degree (BA) is also from Yale University (1999). Her primary research focus centers on gastrointestinal cancers, including esophageal, gastric, pancreatic, hepatic, rectal, and anal cancers, with special expertise in stereotactic body radiotherapy (SBRT) for tumors of the chest and abdomen. She also treats lung cancer, head and neck cancer, and prostate cancer. Her research aims to define molecular markers using retrospective studies, clinical trials, and translational research to guide treatment decisions and improve outcomes for patients with gastrointestinal malignancies. She is particularly interested in integrating biology-guided radiotherapy approaches and optimizing treatment protocols through clinical trials. Analysis of Dr. Johung's recent publication record reveals a strong focus on gastrointestinal malignancies, particularly pancreatic, rectal, and esophageal cancers. Her work spans clinical guidelines development (NCCN), translational research on molecular biomarkers, technical innovations in radiotherapy delivery (including SBRT and biology-guided radiotherapy), and clinical trial design. A notable trend is her increasing involvement in multi-institutional collaborations and national guideline committees, reflecting her growing influence in the field of radiation oncology for gastrointestinal cancers. Dr. Johung is an active participant in national cancer guideline development, serving on NCCN panels for Esophageal and Gastric Cancers. Her clinical expertise has been recognized through inclusion in Yale Medicine's 'Top Doctors' lists. She is also a member of the American Society for Radiation Oncology, contributing to the advancement of the field through professional engagement. As Director of the Residency Training Program, Dr. Johung oversees the education and development of future radiation oncologists at Yale. She has led research on resident evaluation methods and faculty assessment across radiation oncology programs nationally. Her clinical trials portfolio includes studies on stereotactic body radiation therapy for oligoprogression on immune checkpoint inhibitors in metastatic renal cell carcinoma (as Principal Investigator) and participation as Sub Investigator in trials for MRI brain surveillance versus prophylactic cranial irradiation in small-cell lung cancer and dose-deescalated SBRT for centrally located lung cancer. Dr. Johung is affiliated with multiple research teams including the Center for Gastrointestinal Cancers, DNA Damage and Genome Integrity team, Gastrointestinal Radiotherapy Program, Pancreatic Diseases Program, and Prostate & Genitourinary Radiotherapy team at Yale Cancer Center. These affiliations reflect her collaborative approach to cancer research and treatment across multiple disciplines within the Yale ecosystem.

• Oncology
• Clinical Trials
• Gastrointestinal Cancers
• +۳ مورد دیگر

Associate Professor Katrin Sjoquist is a Senior Research Fellow and Clinical Lead at the NHMRC Clinical Trials Centre (CTC), part of the Faculty of Medicine and Health at the University of Sydney. She is also a practising medical oncologist specializing in gastrointestinal and rare cancers. Since joining the CTC in 2010, she has focused on clinical trials in oncology, earning a PhD in clinical trial design and evaluation. Her roles include coordinating the AGITG trials and leading the Cancer Australia-funded Genomics Cancer Clinical Trials Initiative (GCCTI) and the Molecular Screening and Therapeutics (MoST) programme. Research Interests: Design and management of Phase II/III clinical trials, evidence-based medicine, gastrointestinal and rare cancers, and evaluating treatment benefits versus harms. Her work spans oncology drug development, precision medicine, and translational research. Publications: Over 100 peer-reviewed articles, including high-impact studies in Journal of Clinical Oncology , Clinical Cancer Research , and British Journal of Cancer . Recent work focuses on regorafenib in gastric cancer, cell-free DNA biomarkers, and clinical trial methodologies. Grants and Leadership: Principal investigator on grants such as the Biliary Tract Registry Development (2023), and leadership roles in international trials like INTEGRATE II and NuTide:121. Collaborates with institutions like the Garvan Institute. Labs/Teams: CTC, AGITG, and MoST programme. Her work emphasizes collaborative, multi-institutional research to advance oncology treatments.

• Radiation Oncology
• Particle Therapy
• Medical Physics
• +۴ مورد دیگر

Professor J. Debus is a distinguished academic in Radiation Oncology at Heidelberg University's Medical Faculty, with extensive research focused on particle therapy, medical physics, and cancer treatment optimization. His work spans clinical trials, radiobiology, and technical innovations in radiation delivery systems. Primary Affiliation: German Cancer Research Center (DKFZ), Heidelberg Research Focus: Particle therapy, radiation oncology, medical physics Key Collaborations: Mein S., Liew H., Tessonnier T., and other leading researchers in radiation oncology Professor Debus' research interests center on advancing particle therapy techniques including proton, carbon ion, and emerging modalities like helium and oxygen ion therapy. His work addresses critical challenges in radiation oncology such as normal tissue sparing, hypoxia-induced radioresistance, and precision treatment delivery. He has made significant contributions to understanding the biological effects of different radiation types and optimizing treatment protocols for various cancer types including head and neck cancers, brain metastases, and prostate cancer. His recent publications demonstrate leadership in clinical trials (GUARD, ESTRON, PROBASE) and technical innovations in radiation delivery systems, particularly in the emerging field of FLASH radiotherapy and ultra-high dose rate treatments. Professor Debus has published extensively on treatment planning optimization, radiation-induced biological effects, and imaging techniques for precise radiation delivery. Leading clinical trials in particle therapy Developing novel techniques for normal tissue protection Advancing understanding of radiation biology across different modalities Professor Debus has secured significant research funding for his work in radiation oncology and particle therapy. His research has contributed to clinical implementation of advanced treatment techniques at the Heidelberg Ion-Beam Therapy Center (HIT), one of the world's leading facilities for particle therapy. He supervises numerous doctoral students and postdoctoral researchers in the radiation oncology field. His laboratory and research team focus on translational research bridging basic radiobiology with clinical applications, with particular emphasis on optimizing treatment protocols for challenging tumor types and improving patient outcomes through precision radiation therapy.

• Biostatistics
• Environmental Dose-Response Modeling
• Quantitative Risk Assessment
• +۷ مورد دیگر

Paul J. Catalano is a Senior Lecturer in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health. He is affiliated with the Dana-Farber Cancer Institute, where he serves as a statistician for clinical trials and collaborates on cancer research. His research focuses on biostatistical methods for analyzing multiple outcomes and repeated measures in environmental dose-response modeling, quantitative risk assessment, and neurotoxicity studies. He also develops software for implementing modeling algorithms and investigates experimental design in low-dose risk estimation. Recent publications highlight collaborations in immunotherapy for urothelial carcinoma radiation therapy for brain metastases pediatric neuroblastoma treatment AI-driven MRI segmentation . Dr. Catalano's work extends to clinical trials in colorectal, genito-urinary, and breast cancer, with emphasis on prognostic factor identification and translational research.

• Health economics
• Health technology assessment
• Measurement of quality of life
• +۴ مورد دیگر

Jane Hall is a Distinguished Professor of Health Economics at the Centre for Health Economics Research and Evaluation (CHERE) within the Faculty of Health at the University of Technology Sydney (UTS). She is a Fellow of the Academy of Social Sciences in Australia and a Fellow of the Australian Academy of Health and Medical Sciences. Professor Hall serves on the Independent Health and Aged Care Pricing Authority and has been instrumental in shaping health economics research and policy in Australia through her extensive national and international committee work. Professor Hall earned her PhD from the University of Sydney in 1994. She was the founding Director of CHERE, established in 1990, and led the center until 2012. Her leadership has significantly contributed to the development of health economics as a discipline in Australia, building institutional capacity and professional networks that continue to influence health policy development. Professor Hall's research program spans multiple dimensions of health economics, with a current focus on healthcare financing and funding mechanisms to improve system performance. Her work examines health technology assessment, measurement of quality of life, end-of-life care economics, health workforce issues, and primary care economics. Recent publications reveal a strong emphasis on out-of-pocket costs, Medicare sustainability, geographic disparities in healthcare access, and value-based payment reform. Her methodological approaches include sophisticated econometric analyses, discrete choice experiments, and health services research designs that bridge theoretical economics with practical policy applications. Her scholarly contributions demonstrate consistent thematic development across healthcare financing models, with particular attention to equity implications and system performance metrics. The articles show progression from foundational work on health technology assessment to current research addressing complex challenges in healthcare financing amid rising costs and demographic pressures. Officer in the Order of Australia (AO) 2023 Fellow of the Academy of Social Sciences in Australia Fellow of the Australian Academy of Health and Medical Sciences UTS Distinguished Service Award 2019 National Health and Medical Research Council Outstanding Contribution Award 2017 Australian Financial Review/Westpac 100 Women of Influence 2016 Inaugural Professional Award of the Health Services Research Association of Australia and New Zealand 2011 Professor Hall has been actively engaged in professional leadership throughout her career, serving as Past President of the Academy of Social Sciences in Australia, the Health Services Research Association of Australia and New Zealand, and the International Health Economics Association. Her work has attracted significant research funding through collaborations with government bodies seeking evidence to inform health policy decisions. She maintains an extensive international network through her long-term involvement with the Commonwealth Fund International Program in Health Policy and Practice. As founder and former Director of CHERE, Professor Hall established a vibrant research center that brings together interdisciplinary teams working collaboratively with policymakers, healthcare providers, and other stakeholders. The center continues to conduct high-impact research addressing complex challenges in healthcare financing and delivery, building on the foundation she established over three decades ago.

Gaurav Marwahaمشاهده پروفایل

دانشیار

• Radiation Oncology
• Lung Cancer
• Stereotactic Radiosurgery
• +۳ مورد دیگر

Gaurav Marwaha, MD is an Associate Professor in the Department of Radiation Oncology at Rush Medical College, Rush University. He maintains clinical practice across multiple locations including RUSH MD Anderson Cancer Center in Chicago, Rush Radiation Oncology - Oak Park, Rush Lung Center - Oak Park, and RUSH MD Anderson Cancer Center at Rush Lisle. His work focuses on providing cutting-edge radiation therapy while emphasizing compassionate patient care, stating that being part of curing early-stage cancers or alleviating discomfort is the most rewarding aspect of being a physician. Dr. Marwaha's research interests span radiation oncology with particular expertise in lung cancer treatment, stereotactic radiosurgery, brachytherapy, and ocular oncology. His clinical expertise includes brain tumors, chest tumors, esophageal cancer, Hodgkin lymphoma, intensity-modulated radiation therapy, mediastinal tumors, mesothelioma, non-Hodgkin lymphoma, palliative radiation therapy, spinal cancers, and thymoma. His approach emphasizes multidisciplinary care, telling patients 'we got you and we got this, and you have a team here' to navigate their cancer journey. His publication record shows a consistent focus on advancing radiation oncology techniques and addressing systemic issues in cancer care. The most recent works examine difficult decisions in non-small cell lung cancer treatment, chemoradiation protocols for elderly patients, automated treatment planning, and workforce dynamics in radiation oncology. His research bridges technical advancements in radiation delivery with broader considerations of patient care and professional development in the field. Dr. Marwaha is board certified in Radiation Oncology with educational background from University of Cincinnati College of Medicine (medical school) and Cleveland Clinic Foundation (residency). He emphasizes that radiation oncology sits at 'the crossroads of so many fields within cancer care,' highlighting how advancements have enabled higher quality treatment with less impact on patients' lives while maintaining excellent outcomes.

• Radiation Oncology
• Brachytherapy
• Stereotactic Radiosurgery (SRS)
• +۷ مورد دیگر

Venita L. Williams, M.D., is an Assistant Clinical Professor in the Department of Radiation Oncology at City of Hope, Duarte, CA, a position she has held since 2018. She is also a practicing Radiation Oncologist at St. Joseph Hospital of Orange since 2008. Her clinical expertise spans a wide range of cancers, including brain tumors, head and neck cancers, sarcoma, lymphoma, breast, lung, gastrointestinal, gynecologic, and pediatric malignancies. Education: B.S., University of California, Los Angeles (UCLA), 1998 M.D., University of Rochester School of Medicine & Dentistry, 2003 Internal Medicine Internship, Loma Linda University Medical Center, Loma Linda, CA (2003–2004) Radiation Oncology Residency, University of California Irvine, City of Hope, Long Beach Memorial, and Long Beach VA Medical Centers (2004–2008) Dr. Williams specializes in advanced radiation techniques such as SRS, SBRT, IMRT, and intraoperative radiotherapy (Mobetron), and is trained in Optune therapy. She has a strong interest in Integrative Oncology, emphasizing holistic care during cancer treatment. Her research focuses on enhancing radiotherapy efficacy through technological innovation and combination therapies. Her sole published article explores the use of interstitial hyperthermia during HDR brachytherapy for early-stage prostate cancer, highlighting her focus on improving treatment outcomes through combined modalities. Professional Memberships: American Brachytherapy Society (2007) American Society for Therapeutic and Radiation Oncology (2004) Association of Residents in Radiation Oncology (2004) Radiological Society of North America (2004) American College of Radiology (2004) American Academy of Hospice and Palliative Medicine (2002) American Medical Association (1998) Dr. Williams is actively involved in patient education and clinical trials, contributing to both local and international research protocols. She has no listed advisees or formal grants, but her multidisciplinary training and technological expertise position her as a key contributor to modern radiation oncology practice. She is fluent in Spanish and Taiwanese.

Richard De Abreu Lourencoمشاهده پروفایل

استاد

• Applied Economics
• Public Health
• Health Economics
• +۵ مورد دیگر

Professor Richard De Abreu Lourenco is affiliated with the University of Technology Sydney (UTS) as a faculty member in the Faculty of Health , specifically within the Centre for Health Economics Research and Evaluation (CHERE) since 2024. Previously, he held academic roles at UTS including Associate Professor (2018-2023), Senior Research Fellow (2016-2018), and Research Fellow (2013-2016). His non-academic career includes leadership roles at Covance (2006-2013) and Novartis Pharmaceuticals (2001-2006). Education: PhD, University of Technology Sydney (2017) Master of Economics, University of Sydney (1997) Bachelor of Economics, Murdoch University (1992) Research Focus: His work spans applied economic evaluations , specialty health economics (particularly oncology/haematology ), patient preference modeling , and priority setting in healthcare . He explores cost-effectiveness of emerging therapies (CAR-T, SABR radiotherapy), health technology assessment (HTA) , and value frameworks for high-cost treatments . Recent Trends: Recent publications analyze access pathways for rare disease drugs , methodological challenges in discrete choice experiments , cost-effectiveness of radiotherapy vs. ablation , and genetic risk stratification in endocrine tumors . Collaborative work spans oncology , public health policy , and diagnostic testing preferences . Supervision & Grants: Available for Masters and PhD supervision . Leads funded research projects including generative AI in pharmaceutical evaluation , digital health for culturally diverse prostate cancer patients , and economic frameworks for high-cost therapies . Collaborates with institutions like Novartis , Covance , and Cancer Australia .

• Oncology
• Radiotherapy
• Palliative Care
• +۴ مورد دیگر

Astrid Dalhaug serves as a University Lecturer at the Department of Clinical Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway. Her academic work focuses on clinical oncology with particular emphasis on cancer treatment outcomes in rural healthcare settings across Northern Norway. Dr. Dalhaug's research interests center on oncology, specifically radiotherapy, palliative care, and survival prediction models for cancer patients. Her work frequently addresses the challenges of delivering quality cancer care in remote regions with scattered populations. She investigates prognostic factors in various cancer types including prostate cancer, lung cancer, and brain metastases, with special attention to biomarkers, treatment fractionation, and demographic variables that influence patient outcomes. Analysis of her publication record reveals a consistent focus on developing and validating practical prognostic tools for clinical use, particularly the LabPS and LabBM scores. Her research demonstrates how serum biomarkers can enhance survival prediction accuracy across different cancer types and metastatic presentations. A distinctive feature of her work is the examination of rural healthcare delivery challenges and their impact on cancer treatment outcomes in Northern Norway's unique geographical context. Dr. Dalhaug maintains a highly productive research collaboration, most notably with Carsten Nieder, with whom she has co-authored numerous studies across multiple cancer types and treatment modalities. Her work spans clinical trials, retrospective analyses, and validation studies that contribute significantly to evidence-based oncology practice, particularly in resource-limited or geographically isolated settings.

Mats Christiansenمشاهده پروفایل

مدرس

• LGBTQ Health
• Prostate Cancer Care
• Health Literacy
• +۵ مورد دیگر

Mats Christiansen is a University Lecturer at Uppsala University and doctoral student in Health Sciences at Åbo Akademi University. His primary affiliation is with the Faculty of Education and Welfare Studies. He holds a PhD in progress, a Licentiate from Karolinska Institutet, and multiple nursing degrees. Education highlights include: Phil. Dr. (ongoing), Åbo Akademi University Licentiate in Prostate Cancer Care, Karolinska Institutet (2019) Master of Science in Elderly Care Nursing, Karolinska Institutet (2021) University of Gothenburg degrees (BA 1999, MA 1999) Research focuses on LGBTQ+ health equity, particularly prostate cancer care for MSM, aging populations, and mHealth interventions. Key themes include: Sexual health post-cancer treatment Health literacy and self-care strategies Queer theory applied to healthcare Stigma reduction in clinical settings Recent projects include netnography studies on prostate cancer survivorship and a 2021-2023 initiative on sexual health after treatment. Active in peer review for Qualitative Health Research and Higher Education journals. Awards include the Chancellor's GLBT Leadership Award (2010) and a 2023 research prize. Engaged in public speaking on LGBTQIA+ health issues and sits on the Public Health Agency of Sweden’s HIV/hepatitis advisory board. Current work involves studying sexual health trajectories among MSM prostate cancer survivors and exploring AI ethics in medical education contexts.

• Cancer Policy
• Health Services Research
• Global Health
• +۷ مورد دیگر

Professor Ajay Aggarwal is a leading academic in Cancer Services and Systems Research at the London School of Hygiene & Tropical Medicine (LSHTM) and a Consultant Clinical Oncologist at Guy’s & St Thomas’ NHS Trust. His work bridges clinical practice and health policy, focusing on cancer care quality, global health equity, and innovative technologies like AI in radiotherapy. PhD, LSHTM MSc, LSHTM (Health Services Research) MSc, Institute of Cancer Research (Cancer Science) BSc, King’s College London (Medicine) BSc, Imperial College London (Management) His research explores cancer policy, performance assessment of cancer care, and global health systems. He employs mixed methods to analyze large clinical datasets, addressing affordability of cancer care, value of technologies, and health disparities. His work influences WHO taskforces and European cancer policy. Recent publications span quality improvement (e.g., national cancer audits), global health equity (e.g., Zambia cancer mapping), AI applications in radiotherapy , and health policy implementation (e.g., guideline adherence in prostate cancer). Themes include healthcare accessibility, technology assessment, and equity-focused interventions. NIHR Research Fellowship (2014, 2020) NHS National Clinical Impact Award (2022-2026) Wellcome Trust Digital Innovator Award (2021-2023) Advanced Fellowship (2020) Doctoral Research Fellowship (2014-2017) As Editor-in-Chief of the Journal of Cancer Policy , he shapes global discourse. He teaches postgraduate public health students, leads international workshops (CREDO), and trains professionals in radiation oncology quality management. His grants from NIHR, Wellcome Trust, and US NIH support research on AI in radiotherapy and health disparities.

Borna Maraghechiمشاهده پروفایل

پزشک-پژوهشگر

• Medical Physics
• Radiation Oncology
• Image-Guided Radiotherapy
• +۳ مورد دیگر

Borna Maraghechi is a Clinical Physicist in the Department of Radiation Oncology at Washington University School of Medicine, St. Louis, MO. He completed his academic and professional training in Iran, Canada, and the U.S., including a residency in Therapy Medical Physics at WashU. BSc in Physics (2009), Amirkabir University of Technology, Tehran, Iran MSc in Physics (2012), Laurentian University, Sudbury, Canada PhD in Biomedical Physics (2016), Ryerson University, Toronto, Canada Residency in Therapy Medical Physics (2020), Washington University School of Medicine His research focuses on advanced radiotherapy techniques, particularly MR-guided adaptive therapy, dosimetry innovation, and quality assurance for emerging treatment modalities. He develops methods for precision radiation delivery in complex anatomical regions, with emphasis on gastrointestinal and pancreatic cancers. His recent work spans 2020–2025, addressing challenges in cone-beam CT for proton therapy, toxicity prediction models, and automated quality assurance. Key themes include medical imaging integration, treatment personalization, and safety protocols for adaptive radiation therapy. Certified by the American Board of Radiology in Therapeutic Medical Physics (2021)